Glatiramer (Multiple Sclerosis)

The phrase "Glatiramer (Multiple Sclerosis)" represents an indication-specific reference grouping rather than a distinct formal pharmacological drug class, referring specifically to the immunomodulatory agent glatiramer acetate Therapeutics centered on glatiramer are indicated for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults

The phrase "Glatiramer (Multiple Sclerosis)" represents an indication-specific reference grouping rather than a distinct formal pharmacological drug class, referring specifically to the immunomodulatory agent glatiramer acetate

Glatiramer is a synthetic copolymer consisting of four amino acids designed to mimic myelin basic protein It is thought to act as an immunomodulator by competitively binding to major histocompatibility complex molecules, suppressing myelin-reactive T cells, and promoting a phenotypic shift toward neuroprotective, anti-inflammatory T-helper 2 and regulatory T cells

Glatiramer is a synthetic copolymer consisting of four amino acids designed to mimic myelin basic protein It is thought to act as an immunomodulator by competitively binding to major histocompatibility complex molecules, suppressing myelin-reactive T cells, and promoting a phenotypic shift toward neuroprotective, anti-inflammatory T-helper 2 and regulatory T cells

It is thought to act as an immunomodulator by competitively binding to major histocompatibility complex molecules, suppressing myelin-reactive T cells, and promoting a phenotypic shift toward neuroprotective, anti-inflammatory T-helper 2 and regulatory T cells

Therapeutics centered on glatiramer are indicated for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults